Endoscopy 2026; 58(04): 438
DOI: 10.1055/a-2793-0676
Letter to the editor

Photometric capsule in nonvariceal upper gastrointestinal hemorrhage: is a 120-minute window sufficient for high-risk patients?

Authors

  • Jianfeng Luo

    1   Graduate School, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Ringgold ID: RIN12501)

10.1055/a-2679-6906

I read with interest the pilot study by Brand et al. regarding the use of photometric capsule examination (PCE) to triage patients with nonvariceal upper gastrointestinal hemorrhage (NVUGIH) [1]. While the 100% negative predictive value for active bleeding is encouraging, its clinical implementation, especially in high-risk cohorts (median Glasgow–Blatchford bleeding score [GBS] of 11), raises critical safety concerns.

First, current European Society of Gastrointestinal Endoscopy guidelines emphasize that patients with GBS >1 require early endoscopy within 24 hours [2]. The authors’ protocol, which delayed endoscopy to 48–96 hours based on a negative PCE, directly challenges this safety standard. As NVUGIH is often characterized by intermittent bleeding, a 120-minute sensing window may provide a false sense of security. As demonstrated in a landmark trial, delaying endoscopy in high-risk patients (GBS ≥12) is associated with increased risks [3]. Notably, two patients in the PCE-negative group in the Brand et al. study required emergency endoscopy due to clinical deterioration, reinforcing that “no active blood” at one time point does not guarantee stability in a high-risk GBS population [4].

Second, the low positive predictive value (28%) for active bleeding suggests that PCE significantly overestimates the need for urgent intervention when blood is detected [1] [5]. In resource-limited settings, this could lead to unnecessary emergency procedures, potentially counteracting the capsule’s intended benefit of optimizing resource allocation.

In conclusion, while PCE is a promising triage adjunct, it should not yet supersede clinical risk scores or established timing guidelines for high-risk patients. Future randomized trials must prioritize clinical outcomes, such as rebleeding and mortality, rather than just the rate of avoided procedures.



Publication History

Article published online:
20 March 2026

© 2026. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany